Skip to main content
Premium Trial:

Request an Annual Quote

T2 Biosystems Regains Compliance With Nasdaq Listing Requirements

NEW YORK – T2 Biosystems announced Wednesday it has regained compliance with the Nasdaq's minimum bid price continued listing requirement. 

In April, the company was notified it wasn't in compliance with the requirement because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. 

The Lexington, Massachusetts-based firm regained compliance by maintaining a minimum closing bid price of at least $1.00 for 10 consecutive trading days, which it did on June 15.

At the close of the market Tuesday, T2 Bio shares were down nearly 6 percent at $1.54.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.